peterschreiber.media
JP Morgan upgraded Bruker (NASDAQ:BRKR) to overweight, citing its better-than-expected 2024 guidance and pull-forward of its 2026 revenue and non-GAAP EPS LRP targets to 2025.
“Ultimately, we walked away impressed by BRKR’s 2024 guide, off a tough comp, and the confidence in the long-term sustainability in growth suggested by the LRP pull-forward and believe BRKR seems poised to become a leading player in this shift in research focus toward proteomics," wrote the analysts in their note.
JP Morgan raised its price target for Bruker to $90 from $60.
More on Bruker
- Bruker Corporation (BRKR) Q4 2023 Earnings Call Transcript
- Bruker And JEOL: Assessing The NMR Market Leaders
- Bruker Corporation (BRKR) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
- Bruker Non-GAAP EPS of $0.70 beats by $0.04, revenue of $854.5M beats by $49.79M
- Bruker Q4 2023 Earnings Preview